Latest Conference Articles

January 6th 2022, 2:00pm

SABCS

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

January 5th 2022, 8:15pm

SABCS

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

January 5th 2022, 5:00pm

American Society of Hematology Annual Meeting

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

January 3rd 2022, 10:00pm

SABCS

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

December 28th 2021, 4:00pm

SABCS

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

December 27th 2021, 10:00pm

SABCS

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.

December 20th 2021, 8:00pm

SABCS

Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.

December 15th 2021, 7:00pm

American Society of Hematology Annual Meeting

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

December 15th 2021, 2:00pm

American Society of Hematology Annual Meeting

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

December 14th 2021, 10:00pm

The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant.

December 14th 2021, 8:00pm

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

December 14th 2021, 2:00pm

American Society of Hematology Annual Meeting

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

December 13th 2021, 10:00pm

American Society of Hematology Annual Meeting

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

December 13th 2021, 9:00pm

American Society of Hematology Annual Meeting

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

December 13th 2021, 8:00pm

American Society of Hematology Annual Meeting

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

December 13th 2021, 2:30pm

American Society of Hematology Annual Meeting

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

December 12th 2021, 10:00pm

American Society of Hematology Annual Meeting

Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone.

December 12th 2021, 8:00pm

SABCS

Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.

December 12th 2021, 5:11pm

American Society of Hematology Annual Meeting

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

December 12th 2021, 3:00pm

American Society of Hematology Annual Meeting

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

December 11th 2021, 10:00pm

American Society of Hematology Annual Meeting

Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.

December 11th 2021, 6:34pm

American Society of Hematology Annual Meeting

Recent results demonstrated durable responses and no new side effects for Venclexta plus Imbruvica in pretreated chronic lymphocytic leukemia.

December 11th 2021, 4:00pm

American Society of Hematology Annual Meeting

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

December 11th 2021, 3:00pm

SABCS

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

December 10th 2021, 10:00pm

SABCS

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

December 10th 2021, 8:00pm

American Society of Hematology Annual Meeting

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

December 10th 2021, 5:00pm

SABCS

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

December 10th 2021, 2:00pm

SABCS

Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.

December 9th 2021, 10:00pm

SABCS

Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.

December 8th 2021, 10:00pm

SABCS

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.